Back to all announcements

DJ First Sentinel Plc Investment of Capital in Stabilitech Biopharma Limited

 
TIDMFSEN 
 
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR 
INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, RUSSIA, THE 
REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD 
CONSTITUTE A BREACH OF THE RELEVANT SECURITIES LAWS OF SUCH JURISDICTION. 
 
This announcement does not constitute a prospectus or offering memorandum or an 
offer in relation to any securities of First Sentinel Plc or of any other 
entity and should not be considered as a recommendation that any person should 
subscribe for or purchase any such securities. 
 
This announcement contains inside information for the purposes of the Market 
Abuse Regulation (EU No. 596/2014) ("MAR"). Upon the publication of this 
announcement, this inside information is now considered to be in the public 
domain and shall therefore cease to be inside information. 
 
Friday 22 May 2020 
 
                              First Sentinel Plc 
                      ("First Sentinel" or the "Company") 
 
First Sentinel announces Investment of Capital in Stabilitech Biopharma Limited 
                               ("Stabilitech"). 
 
 
 
 
Alternative investment company First Sentinel Plc is pleased to announce today 
that it has invested a total of GBP270,000 in Stabilitech Biopharma Limited 
through the acquisition of 23,336 ordinary shares giving First Sentinel an 
equity interest of approximately 0.675% in Stabilitech following the closing of 
the current GBP6m funding round currently being conducted. 
 
In conjunction with this, their partner company First Sentinel Corporate 
Finance has been appointed as Stabilitech's fundraising advisor with respect to 
the current private capital raise. 
 
Stabilitech is a UK based biotechnology company developing next generation 
vaccines and biopharmaceuticals since 2005. Currently, Stabilitech is focused 
on the development of OraPro-COVID-19, an oral vaccine that provides double 
immunity, can be self- administered and delivered by post. 
 
More than 50% of vaccines worldwide are lost because of cold-chain storage, as 
regular vaccines require storage conditions of -20 to -80C, which is extremely 
hard to maintain during transportation. What is unique about Stabilitech's 
vaccine-in-a-capsule technology is that the capsules are thermally stable and 
thus can be transported at temperatures up to 50C. 
 
After a successful safety animal trial, clinical trials are expected to start 
in June and the thermally stable oral vaccine could be available for 
distribution by the end of 2020. 
 
About First Sentinel 
 
First Sentinel is an alternative investment company, registered with the FCA as 
a small authorised UK AIFM, which provides growth capital for public and 
private company investments. First Sentinel invests in a range of debt and 
equity instruments in target portfolio companies. 
 
The Company's website is www.first-sentinel.com 
 
For further corporate information, please contact: 
 
Mr. Brian Stockbridge 
 
CEO 
 
First Sentinel Plc 
 
Tel: + 44 (0) 7876 888 011 
 
AQSE Corporate Advisor 
Beaumont Cornish Limited 
James Biddle / Roland Cornish 
Tel: +44(0)20 7628 3396 
 
 
 
END 
 

(END) Dow Jones Newswires

May 22, 2020 02:00 ET (06:00 GMT)